Pandemic H5N1 influenza vaccine development: an update

References

• Patterson KD, Pyle GF. The geography and mortality of the 1918 influenza pandemic. Bull. Hist. Med.65, 4–21 (1991).
   PubMed Web of Science ®Google Scholar
• Taubenberger JK, Morens DM. 1918 influenza: the mother of all pandemics. Emerg. Infect. Dis.12, 15–22 (2006).
   PubMed Web of Science ®Google Scholar
• Glezen PW. Emerging infections: pandemic influenza. Epidemiol. Rev.18, 64–76 (1996).
   PubMed Web of Science ®Google Scholar
• Webster RG, Wright SM, Castrucci MR et al. Influenza – a model for an emerging infectious disease. Intervirology35, 16–25 (1993).
   PubMed Web of Science ®Google Scholar
• Eickhoff TC, Sherman IL, Serfling RE. Observations on excess mortality associated with epidemic influenza. JAMA176, 776–782 (1961).
   PubMed Web of Science ®Google Scholar
• Chin TD, Foley JF, Doto IL, Gravelle CR, Weston J. Morbidity and mortality characteristics of Asian strain influenza. Public Health Rep.75, 148–158 (1960).
   PubMedGoogle Scholar
• Sharrar RG. National influenza experience in the USA, 1968–69. Bull. World Health Organ41, 361–366 (1969).
   PubMed Web of Science ®Google Scholar
• Bean WJ, Schell M, Katz J et al. Evolution of the H3 influenza virus hemagglutinin from human and nonhuman hosts. J. Virol.66, 1129–1138 (1992).
   PubMed Web of Science ®Google Scholar
• Chen H, Smith GJ, Li KS et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc. Natl Acad. Sci. USA103, 2845–2850 (2006).
   PubMed Web of Science ®Google Scholar
• Ducatez MF, Olinger CM, Owoade AA et al. Avian flu: multiple introductions of H5N1 in Nigeria. Nature442, 37 (2006).
   PubMed Web of Science ®Google Scholar
• Pattnaik B, Pateriya AK, Khandia R. Phylogenetic analysis revealed genetic similarity of the H5N1 avian influenza viruses isolated from HPAI outbreaks in chickens in Maharashtra, India with those isolated from swan in Italy and Iran in 2006. Curr. Sci.91, 77–81 (2006).
   Web of Science ®Google Scholar
• Guan Y, Poon LL, Cheung CY et al. H5N1 influenza: a protean pandemic threat. Proc. Natl Acad. Sci. USA101, 8156–8161 (2004).
   PubMed Web of Science ®Google Scholar
• Li KS, Guan Y, Wang J et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in Eastern Asia. Nature430, 209–213 (2004).
   PubMed Web of Science ®Google Scholar
• Zhu QY, Qin ED, Wang W et al. Fatal infection with influenza A (H5N1) virus in China. N. Engl. J. Med.354, 2731–2732 (2006).
   PubMed Web of Science ®Google Scholar
• Lin YP, Shaw M, Gregory V et al. Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc. Natl Acad. Sci. USA97, 9654–9658 (2000).
   PubMed Web of Science ®Google Scholar
• Koopmans M, Wilbrink B, Conyn M et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet363, 587–593 (2004).
   PubMed Web of Science ®Google Scholar
• WHO Writing Group. Nonpharmaceutical interventions for pandemic influenza, international measures. Emerg. Infect. Dis.12, 81–87 (2006).
   PubMed Web of Science ®Google Scholar
• WHO Writing Group. Nonpharmaceutical interventions for pandemic influenza, national and community measures. Emerg. Infect. Dis.12, 88–94 (2006).
   PubMed Web of Science ®Google Scholar
• Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature442, 448–452 (2006).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Bugarini R, Nicholson KG et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis.191, 1210–1215 (2005).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Nicholson KG, Colegate A et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine21, 1687–1693 (2003).
   PubMed Web of Science ®Google Scholar
• Webby RJ, Perez DR, Coleman JS et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet363, 1099–1103 (2004).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine19, 1732–1737 (2001).
   PubMed Web of Science ®Google Scholar
• Suquitan AL Jr, McAuliffe J, Mills KL et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med.3, e360 (2006).
   Google Scholar
• Lu X, Edwards LE, Desheva JA et al. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine24, 6588–6593 (2006).
   PubMed Web of Science ®Google Scholar
• Lin J, Zhang J, Dong X et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a Phase I randomised controlled trial. Lancet368, 991–997 (2006).
   PubMed Web of Science ®Google Scholar
• Hoelscher MA, Garg S, Bangari DS et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet367, 475–481 (2006).
   PubMed Web of Science ®Google Scholar
• Kodihalli S, Goto H, Kobasa DL, Krauss S, Kawaoka Y, Webster RG. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J. Virol.73, 2094–2098 (1999).
   PubMed Web of Science ®Google Scholar
• Ernst WA, Kim HJ, Tumpey TM et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine24, 5158–5168 (2006).
   PubMed Web of Science ®Google Scholar
• Epstein CL, Kong WP, Misplon JA et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine23, 5404–5410 (2005).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Wood JM, Nicholson KG, Zambon MC. Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J. Med. Virol.70, 391–398 (2003).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res.103, 91–95 (2004).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Das RG, Wood JM, Katz JM. Comparison of neutralizing antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine25, 4056–4063 (2007).
   PubMed Web of Science ®Google Scholar
• Wood JM, Gaines-Das RE, Taylor J, Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine12, 167–175 (1994).
   PubMed Web of Science ®Google Scholar
• European Committee for Proprietary Medicinal Products. Note for Guidance on Harmonization of Requirements for Influenza Vaccines. March 1997 (CPMP/BWP/214/96). European Agency for the Evaluation of Medicinal Products. 12 March 1997.
   Google Scholar
• US FDA. Draft guidance for industry on clinical data needed to support the licensure of trivalent inactivated influenza vaccines. Fed. Reg.71, 12367 (2006).
   Google Scholar
• Treanor JJ, Campbell James D, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med.354, 1343–1351 (2006).
   PubMed Web of Science ®Google Scholar
• Bresson JL, Perrone C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet367, 1657–1664 (2006).
   PubMed Web of Science ®Google Scholar
• Keitel W, Campbell J, Treanor J, Walter C, Patel S. A Phase I–II, randomized, controlled, dose ranging study of the safety, reactogenicity, and immunogenicity of intramuscular inactivated influenza A/H5N1 vaccine given alone or with aluminum hydroxide to healthy adults. Presentated at: Options for the Control of Influenza VI. Toronto, Ontario, Canada, 17–23 June 2007 (Abstract).
   Google Scholar
• Brady RC, Treanor JJ, Atmar RL, Chen WH, Winokur P, Belshe R. A Phase I-II, randomized, controlled, dose-ranging study of the safety, reactogenicity, and immunogenicity of intramuscular inactivated influenza A/H5N1 vaccine given alone or with aluminum hydroxide to healthy elderly adults. Presentated at: Options for the Control of Influenza VI. Toronto, Ontario, Canada, 17–23 June 2007 (Abstract).
   Google Scholar
• Minutello M, Senatore F, Cecchinelli G et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive seasons. Vaccine17, 99–104 (1999).
   PubMed Web of Science ®Google Scholar
• Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine19, 2673–2680 (2001).
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Colgate AE, Podda A et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3): a randomized trial of two potential vaccines against H5N1 influenza. Lancet357, 1937–1943 (2001).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Edwards KM, Dekker CL et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza (H5N1) vaccine in adults. J. Infect. Dis. (2008) (Epub ahead of print).
   Google Scholar
• Goji NA, Nolan C, Hill H, Wolff M, Rowe T, Treanor J. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/ 1203/2004 (H5N1) vaccine after priming with an antigenic variant. Presented at: 44th Annual Meeting of the Infectious Diseases Society of America. Toronto, Ontario, Canada, 12–15 October 2006.
   Google Scholar
• Leroux-Roels Barkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomized controlled trial. Lancet370, 580–589 (2007).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Cannon J et al. Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med.351, 2286–2294 (2004).
   PubMed Web of Science ®Google Scholar
• Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N. Engl. J. Med.351, 2295–2301 (2004).
   PubMed Web of Science ®Google Scholar
• Patel SM, Atmar RL, El Sahly H, Cate TR, Keitel WA. A randomized, open-label, Phase I clinical trial comparing the safety, reactogenicity, and immunogenicity of booster immunization with inactivated influenza A/H5N1 vaccine administered by the intradermal (ID) or the intramuscular (IM) route among healthy adults. Presented at: 44th Annual Meeting of the Infectious Diseases Society of America. Toronto, Ontario, Canada, 12–15 October 2006.
   Google Scholar
• Stephenson I, Nicholson KG, Gluck R et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: Phase I randomized trial. Lancet362, 1959–1966 (2003).
   PubMed Web of Science ®Google Scholar
• Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res.103, 163–171 (2004).
   PubMed Web of Science ®Google Scholar